stockrowADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
Follow ADMA
Alert me
ADMA Biologics Inc (ADMA) P/B ratio
As of 5 November 2026, ADMA Biologics Inc (ADMA) trades at a P/B ratio of 6.7×. Over the past ten years it has ranged from 0.0× (June 2017) to 102× (December 2015); the current reading is higher than 60% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 9.1× | (20.49%) |
| FY2024 | 11.5× | 51.95% |
| FY2023 | 7.5× | 49.58% |
| FY2022 | 5.0× | 261.44% |
| FY2021 | 1.4× | (26.76%) |
| FY2020 | 1.9× | (77.07%) |
| FY2019 | 8.3× | 51.93% |
| FY2018 | 5.5× | 191.61% |
| FY2017 | 1.9× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 5.1× | 9.34% |
| Jun 2026 | 4.7× | (14.12%) |
| Mar 2026 | 5.4× | (40.16%) |
| Dec 2025 | 9.1× | 12.25% |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| BHVN Biohaven Ltd. compare | n/m |
| CLDX Celldex Therapeutics, Inc. compare | 3.1× |
| AUPH Aurinia Pharmaceuticals Inc compare | 3.3× |
| IMNM Immunome, Inc. compare | 3.9× |
| VERA Vera Therapeutics, Inc. compare | 5.3× |
| PHVS Pharvaris N.V. compare | 6.4× |
| ADMA ADMA Biologics Inc | 6.7× |
| VCEL Vericel Corporation compare | 6.8× |
| PVLA Palvella Therapeutics, Inc. compare | 10.4× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on ADMA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement